अApnaFunda
Menu

SAKAR HEALTHCARE LIMITED (SAKAR)

Health Technology

Quality scoreHow the business itself ranks against its sector peers on profitability, 3-year growth and leverage. 50 is the middle of the sector.73 / 100
Profitability 61Growth 87Balance sheet 71
Momentum scoreHow strong the recent trend is: 3-month price change, 12-month improvement in earnings and the rise in FII + DII holding, among companies above ₹500 cr.64 / 100
Price 85Earnings 85FII/DII 23
Compare withSUN PHARMACEUTICAL INDUSTRIESDIVIS LABORATORIES LIMITEDTORRENT PHARMACEUTICALS LTD

Passes these screens: High Momentum

Share Price
₹944.80
P/E
58.2x
ROCE
12.0%
Market Cap
₹2102 cr
Revenue (TTM)
₹272 cr
P/S
7.7x
P/B
6.5x
ROE
11.1%
Operating Margin
29.0%
Debt / Equity
0.2x
Promoter Holding
52.5%
12M Momentum
161.6%
P/E vs its own history83rd percentilesince Jun '20
P/E vs Health Technology1.6xthe sector median

52-week range

₹352.00₹1229.85
68% of the way from its 52-week low to its high

Price risk

1Y volatility
56.7%
Beta vs sector
1-year daily
1.13

Balance sheet & cash

Interest cover
operating profit ÷ interest
7.0x
Cash from profit, 3Y
operating cash flow ÷ net profit
1.78x
Share count, 1Y
unchanged

Was the rally earned?

+162%share price, 1 yearEarnings and multiple

Both mattered.

  • Per-share earnings added 99 points and the multiple added 62 points (P/E 40.2x to 58.2x).
  • The share count fell 5%.
1 year Net profit growth: +91 pts. Points of the price return explained by net profit growing (or shrinking).+91 ptsP/E change: +62 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+62 ptsShare count change: +8 pts. Points of the price return explained by the share count changing. More shares count against the price. +162% 1 year Net profit growth: +91 pts. Points of the price return explained by net profit growing (or shrinking).+91 ptsP/E change: +62 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+62 ptsShare count change: +8 pts. Points of the price return explained by the share count changing. More shares count against the price. +162%
Net profit growth+91 ptsNet profit rose about 72%, which lifts the price.
P/E change+62 ptsThe P/E rose from 40.2x to 58.2x, which lifts the price.
Share count change+8 ptsShare count fell 5%, which lifts the price.
+182%share price, 3 yearsEarnings-driven

Mostly yes.

  • Per-share earnings added 155 points to the rise, while the multiple moved less (P/E 50.0x to 58.2x).
  • The share count rose 15%.
3 years Net profit growth: +179 pts. Points of the price return explained by net profit growing (or shrinking).+179 ptsP/E change: +27 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+27 ptsShare count change: -24 pts. Points of the price return explained by the share count changing. More shares count against the price.-24 pts +182% 3 years Net profit growth: +179 pts. Points of the price return explained by net profit growing (or shrinking).+179 ptsP/E change: +27 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.Share count change: -24 pts. Points of the price return explained by the share count changing. More shares count against the price. +182%
Net profit growth+179 ptsNet profit rose about 178%, which lifts the price.
P/E change+27 ptsThe P/E rose from 50.0x to 58.2x, which lifts the price.
Share count change-24 ptsShare count rose 15%, which lowers the price.
+516%share price, 5 yearsEarnings and multiple

Both mattered.

  • Per-share earnings added 245 points and the multiple added 271 points (P/E 22.4x to 58.2x).
  • The share count rose 38%.
5 years Net profit growth: +337 pts. Points of the price return explained by net profit growing (or shrinking).+337 ptsP/E change: +271 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+271 ptsShare count change: -92 pts. Points of the price return explained by the share count changing. More shares count against the price.-92 pts +516% 5 years Net profit growth: +337 pts. Points of the price return explained by net profit growing (or shrinking).+337 ptsP/E change: +271 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+271 ptsShare count change: -92 pts. Points of the price return explained by the share count changing. More shares count against the price. +516%
Net profit growth+337 ptsNet profit rose about 228%, which lifts the price.
P/E change+271 ptsThe P/E rose from 22.4x to 58.2x, which lifts the price.
Share count change-92 ptsShare count rose 38%, which lowers the price.
What do "pts" mean?

"pts" are percentage points of the share price return. The parts add up to the total shown for each period. Because price = P/E × net profit ÷ share count, higher profit pushes the price up, a higher P/E pushes it up, and more shares push it down.

Example: if the price rose 34% and profit growth accounts for +58 pts while a lower P/E accounts for -24 pts, then 58 - 24 = 34. The +58 is not the profit growth rate itself: it is the part of the price move that profit growth explains.

Net profit is trailing twelve months as reported with a 60-day lag.

Compare this with SUN PHARMACEUTICAL INDUSTRIES

Is it expensive against its own past and its peers?

58.3xP/E todayNear its historic high
Against its own history83rd percentileMedian 38.5x; usual range 15.7x to 60.0x since 2020-06.
Against Health Technology58.3x vs 35.4xAbove the Health Technology median.
8.6x29.1x49.6x70.0xJun '20Oct '21Feb '23Jun '24Oct '25Oct '268.6x29.1x49.6x70.0xJun '20Aug '22Oct '24Oct '26
P/E (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

The chart loads when you open this tab.

P/B (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

The chart loads when you open this tab.

P/S (this company)10th to 90th percentile of its own historyIts medianHealth Technology median
How to read this

Shaded band: 10th to 90th percentile of the company's own P/E history; dashed line: its median; orange line: sector median (companies with a positive multiple, at least 5 in the sector).

Sector figures are built from today's listed companies, so they exclude companies that are no longer listed.

All terms explained in the glossary →

How Health Technology is valued

What is the price implying?

~38%annual earnings growth implied by the priceAbove delivered growth

At normalised P/E (five-year average earnings) of 119.1x, a holder earning 12%/yr needs earnings to grow about 37.8%/yr for 10 years, then trade at 15x.

Delivered5.1%/yrEPS, last 7 fiscal years · 3-yr avg to 3-yr avg
Gap+32.7 ptsimplied minus delivered
Rank35thmost demanding of 843

Over time

Implied growth by month (solid) and delivered growth (dashed).

-3%18%40% Jun 2020Oct 2026 -3%18%40% Jun 2020Oct 2026

Change the assumptions

Exit P/E / return11%12%13%
12x39.6%40.9%42.2%
15x36.6%37.8%39.0%
20x32.7%33.9%35.1%
Implied: 37.8%/yr

Looking back

  • Jan 2021Price implied 13%/yr; EPS has since grown 13%/yr (6.0 yrs)
  • Jan 2022Price implied 16%/yr; EPS has since grown 15%/yr (5.0 yrs)

Past comparisons cover only companies listed today (survivorship bias) and say nothing about future outcomes.

“Implied growth” is what the current price would require under our stated assumptions, not what we expect. How this is calculated and the market-wide lists.

What prices imply across Health Technology The market-wide Expectations lists

What changed?

  1. Oct '26Fell 25% from the Sep 2026 peak to the Oct 2026 low.
  2. Oct '26Volume reached 7.5x its 50-day median on 2026-10-23; price -6.5% that day.
  3. Sep '26Volume reached 11.3x its 50-day median on 2026-09-01; price +11.9% that day.
  4. Jun '26Moved into the 3rd quartile of Health Technology on ROCE (from the bottom quartile).
  5. May '26P/E crossed above the 90th percentile of its own history to date (70.1x).
  6. May '26Volume reached 17.5x its 50-day median on 2026-05-18; price +11.9% that day.
  7. Mar '26Moved into the top quartile of Health Technology on operating margin (from the 2nd quartile).
  8. Feb '26Regained the 2024-01 peak, 11 months after the low.
Show 22 earlier events
  1. Feb '26Volume reached 30.2x its 50-day median on 2026-02-05; price +6.1% that day.
  2. Nov '25Volume reached 15.4x its 50-day median on 2025-11-07; price -3.8% that day.
  3. Sep '25Slipped to the bottom quartile of Health Technology on ROCE (from the 3rd quartile).
  4. Sep '25Volume reached 6.6x its 50-day median on 2025-09-23; price +5.0% that day.
  5. Jun '25Moved into the 3rd quartile of Health Technology on ROCE (from the bottom quartile).
  6. Jun '25Volume reached 19.7x its 50-day median on 2025-06-18; price +9.1% that day.
  7. Mar '25Year-on-year EPS growth turned positive.
  8. Mar '25Fell 52% from the Jan 2024 peak to the Mar 2025 low.
  9. Mar '25Moved into the 3rd quartile of Health Technology on EPS growth (from the bottom quartile).
  10. Feb '25Volume reached 14.3x its 50-day median on 2025-02-07; price -1.4% that day.
  11. Jan '25Debt / equity halved over 12 months to 0.30x.
  12. Dec '24Volume reached 9.6x its 50-day median on 2024-12-10; price -5.7% that day.
  13. Sep '24Share count is up 15.8% over 12 months.
  14. Jul '24Volume reached 14.1x its 50-day median on 2024-07-08; price +8.5% that day.
  15. Jun '24Revenue (TTM) reached a new high of ₹153 cr.
  16. Jun '24P/E crossed above the 90th percentile of its own history to date (58.5x).
  17. Jun '24Slipped to the bottom quartile of Health Technology on ROCE (from the 3rd quartile).
  18. Jun '24Debt / equity halved over 12 months to 0.30x.
  19. May '24Volume reached 9.2x its 50-day median on 2024-05-09; price +1.4% that day.
  20. Jan '24Volume reached 14.1x its 50-day median on 2024-01-24; price +6.0% that day.
  21. Dec '23Volume reached 7.8x its 50-day median on 2023-12-26; price +9.8% that day.
  22. Aug '23Regained the 2022-10 peak, 8 months after the low.

Events are generated from the data by fixed rules.
The month shown is when the change became visible in the reported figures, assuming a 60-day lag after each quarter end; it is not an announcement date.

Where price and fundamentals disagree, market-wide Rewind the whole market to any month

Are profits backed by cash?

5 of 7 checks are within range, 2 near a threshold.
Tap a check to see how it is measured.

Other income reliance8%Within range

Other income as a share of pre-tax profit (trailing twelve months): 8.2%. Bands: below 15%, 15% to 35%, above 35%.

Tax rate15%Within range

Median quarterly effective tax rate over about 2.5 years: 15.0%. Bands: 15% to 35%, 5% to 15% or 35% to 50%, outside 5% to 50%.

Cash conversion1.78xWithin range

Operating cash flow divided by net profit over the last three fiscal years: 1.78x (cash from operations ₹107 cr, net profit ₹60 cr). Bands: 0.8x and above, 0.5x to 0.8x, below 0.5x.

Free cash flow2 of 5 yrsNear threshold

Fiscal years with positive free cash flow in the last 5: 2. Bands: at least 80% of years, 40% to 80%, below 40%.

Receivable days vs history+13 daysWithin range

Debtor days are above the median of the previous three fiscal years by 13 days (73 vs 60). Bands: under 15 days, 15 to 45, over 45.

Capital work in progress1% of fixed assetsWithin range

Capital work-in-progress is 1% of fixed assets. Bands: not rising or up to 30%; rising for three years and above 30%; rising and above 60%.

Payable days+33 days / 2 yrsNear threshold

Days payable changed by +33 over two years. Bands: rise of up to 30 days; more than 30 days.

How to read this

Each check is a named rule with fixed thresholds, not a score. Annual statements are the latest restated figures, so a past year may differ from what was originally reported.

All terms explained in the glossary →

Who has been buying and selling?

  • Over 2 years, FIIs trimmed 1.6 pts; DIIs added 0.8 pts; promoters trimmed 0.6 pts.
  • The number of shareholders rose from 7,001 to 14,734 (+110%) between Dec 2023 and Jun 2026.

Holdings, Jun '26

How each group changed

GroupDec '23Jun '26Change
Promoters53.1%52.5%-0.6 pts
FIIs13.8%12.1%-1.6 pts
DIIs10.6%11.4%+0.8 pts
Public and others22.5%24.0%+1.5 pts

Number of shareholders

14,734shareholders+110% since Dec '23
7k10k12k15k Dec '23Sep '24Mar '25Sep '25Mar '26Jun '26
Dec '23: 7,001
Mar '24: 7,386
Sep '24: 7,867
Dec '24: 8,598
Mar '25: 8,608
Jun '25: 8,115
Sep '25: 7,565
Dec '25: 7,069
Mar '26: 9,580
Jun '26: 14,734
 7k10k12k15k Dec '23Dec '24Sep '25Jun '26
Dec '23: 7,001
Mar '24: 7,386
Sep '24: 7,867
Dec '24: 8,598
Mar '25: 8,608
Jun '25: 8,115
Sep '25: 7,565
Dec '25: 7,069
Mar '26: 9,580
Jun '26: 14,734

Quarterly shareholding as reported, labelled by the quarter it covers (it becomes visible about two months later).
Shareholder counts are only available for recent quarters.

This quarter's smart-money board

How rough has the ride been?

Maximum drawdown-52.1%recovered 2026-02
1-year volatility56.7%annualised
Beta vs sector index0.763-year daily, correlation 0.24
Volume spikes4last 90 sessions, 5x the 50-day median

Monthly share price

₹56₹401₹747₹1,093 Jun '20Oct '21Feb '23Jun '24Oct '25Oct '26
2020-06: ₹76.30
2020-07: ₹55.55
2020-08: ₹75.15
2020-09: ₹78.95
2020-10: ₹89.50
2020-11: ₹81.00
2020-12: ₹98.25
2021-01: ₹104.10
2021-02: ₹93.00
2021-03: ₹113.10
2021-04: ₹116.35
2021-05: ₹146.30
2021-06: ₹156.35
2021-07: ₹180.20
2021-08: ₹163.20
2021-09: ₹158.20
2021-10: ₹153.35
2021-11: ₹140.55
2021-12: ₹162.65
2022-01: ₹147.05
2022-02: ₹109.05
2022-03: ₹135.15
2022-04: ₹137.80
2022-05: ₹160.45
2022-06: ₹161.25
2022-07: ₹198.50
2022-08: ₹211.35
2022-09: ₹207.80
2022-10: ₹252.35
2022-11: ₹270.15
2022-12: ₹224.25
2023-01: ₹227.85
2023-02: ₹225.45
2023-03: ₹200.60
2023-04: ₹216.55
2023-05: ₹244.05
2023-06: ₹256.55
2023-07: ₹258.10
2023-08: ₹357.00
2023-09: ₹340.40
2023-10: ₹334.75
2023-11: ₹391.45
2023-12: ₹400.05
2024-01: ₹426.80
2024-02: ₹369.15
2024-03: ₹368.30
2024-04: ₹350.65
2024-05: ₹331.55
2024-06: ₹314.35
2024-07: ₹325.50
2024-08: ₹305.40
2024-09: ₹314.20
2024-10: ₹308.50
2024-11: ₹303.15
2024-12: ₹296.45
2025-01: ₹272.55
2025-02: ₹241.40
2025-03: ₹211.72
2025-04: ₹271.56
2025-05: ₹315.95
2025-06: ₹352.65
2025-07: ₹343.85
2025-08: ₹329.35
2025-09: ₹358.35
2025-10: ₹361.20
2025-11: ₹375.45
2025-12: ₹409.20
2026-01: ₹391.10
2026-02: ₹494.60
2026-03: ₹498.45
2026-04: ₹628.05
2026-05: ₹796.50
2026-06: ₹838.10
2026-07: ₹885.25
2026-08: ₹863.35
2026-09: ₹1093.05
2026-10: ₹944.80
 ₹56₹401₹747₹1,093 Jun '20Aug '22Oct '24Oct '26
2020-06: ₹76.30
2020-07: ₹55.55
2020-08: ₹75.15
2020-09: ₹78.95
2020-10: ₹89.50
2020-11: ₹81.00
2020-12: ₹98.25
2021-01: ₹104.10
2021-02: ₹93.00
2021-03: ₹113.10
2021-04: ₹116.35
2021-05: ₹146.30
2021-06: ₹156.35
2021-07: ₹180.20
2021-08: ₹163.20
2021-09: ₹158.20
2021-10: ₹153.35
2021-11: ₹140.55
2021-12: ₹162.65
2022-01: ₹147.05
2022-02: ₹109.05
2022-03: ₹135.15
2022-04: ₹137.80
2022-05: ₹160.45
2022-06: ₹161.25
2022-07: ₹198.50
2022-08: ₹211.35
2022-09: ₹207.80
2022-10: ₹252.35
2022-11: ₹270.15
2022-12: ₹224.25
2023-01: ₹227.85
2023-02: ₹225.45
2023-03: ₹200.60
2023-04: ₹216.55
2023-05: ₹244.05
2023-06: ₹256.55
2023-07: ₹258.10
2023-08: ₹357.00
2023-09: ₹340.40
2023-10: ₹334.75
2023-11: ₹391.45
2023-12: ₹400.05
2024-01: ₹426.80
2024-02: ₹369.15
2024-03: ₹368.30
2024-04: ₹350.65
2024-05: ₹331.55
2024-06: ₹314.35
2024-07: ₹325.50
2024-08: ₹305.40
2024-09: ₹314.20
2024-10: ₹308.50
2024-11: ₹303.15
2024-12: ₹296.45
2025-01: ₹272.55
2025-02: ₹241.40
2025-03: ₹211.72
2025-04: ₹271.56
2025-05: ₹315.95
2025-06: ₹352.65
2025-07: ₹343.85
2025-08: ₹329.35
2025-09: ₹358.35
2025-10: ₹361.20
2025-11: ₹375.45
2025-12: ₹409.20
2026-01: ₹391.10
2026-02: ₹494.60
2026-03: ₹498.45
2026-04: ₹628.05
2026-05: ₹796.50
2026-06: ₹838.10
2026-07: ₹885.25
2026-08: ₹863.35
2026-09: ₹1093.05
2026-10: ₹944.80

Last 90 trading days

₹800₹930₹1,059₹1,188 Jun 23Jul 20Aug 13Sep 8Oct 6Oct 30
2026-06-23: ₹812.25
2026-06-25: ₹808.05
2026-06-30: ₹838.10
2026-07-02: ₹834.20
2026-07-06: ₹834.95
2026-07-08: ₹800.15
2026-07-10: ₹824.50
2026-07-14: ₹904.45
2026-07-16: ₹896.95
2026-07-20: ₹898.80
2026-07-22: ₹837.25
2026-07-24: ₹802.20
2026-07-28: ₹846.90
2026-07-30: ₹844.40
2026-08-03: ₹922.50
2026-08-05: ₹890.70
2026-08-07: ₹924.65
2026-08-11: ₹953.75
2026-08-13: ₹918.30
2026-08-17: ₹905.35
2026-08-19: ₹871.00
2026-08-21: ₹912.60
2026-08-25: ₹884.85
2026-08-27: ₹892.60
2026-08-31: ₹863.35
2026-09-02: ₹985.80
2026-09-04: ₹1013.90
2026-09-08: ₹1157.85
2026-09-10: ₹1117.30
2026-09-15: ₹1137.55
2026-09-17: ₹1129.55
2026-09-21: ₹1158.45
2026-09-23: ₹1162.65
2026-09-25: ₹1135.85
2026-09-29: ₹1121.85
2026-10-01: ₹1075.00
2026-10-06: ₹1048.50
2026-10-08: ₹1002.40
2026-10-12: ₹981.50
2026-10-14: ₹1020.80
2026-10-16: ₹961.70
2026-10-21: ₹904.80
2026-10-23: ₹889.80
2026-10-27: ₹930.30
2026-10-29: ₹946.50
2026-10-30: ₹944.80
 ₹800₹930₹1,059₹1,188 Jun 23Aug 5Sep 17Oct 30
2026-06-23: ₹812.25
2026-06-25: ₹808.05
2026-06-30: ₹838.10
2026-07-02: ₹834.20
2026-07-06: ₹834.95
2026-07-08: ₹800.15
2026-07-10: ₹824.50
2026-07-14: ₹904.45
2026-07-16: ₹896.95
2026-07-20: ₹898.80
2026-07-22: ₹837.25
2026-07-24: ₹802.20
2026-07-28: ₹846.90
2026-07-30: ₹844.40
2026-08-03: ₹922.50
2026-08-05: ₹890.70
2026-08-07: ₹924.65
2026-08-11: ₹953.75
2026-08-13: ₹918.30
2026-08-17: ₹905.35
2026-08-19: ₹871.00
2026-08-21: ₹912.60
2026-08-25: ₹884.85
2026-08-27: ₹892.60
2026-08-31: ₹863.35
2026-09-02: ₹985.80
2026-09-04: ₹1013.90
2026-09-08: ₹1157.85
2026-09-10: ₹1117.30
2026-09-15: ₹1137.55
2026-09-17: ₹1129.55
2026-09-21: ₹1158.45
2026-09-23: ₹1162.65
2026-09-25: ₹1135.85
2026-09-29: ₹1121.85
2026-10-01: ₹1075.00
2026-10-06: ₹1048.50
2026-10-08: ₹1002.40
2026-10-12: ₹981.50
2026-10-14: ₹1020.80
2026-10-16: ₹961.70
2026-10-21: ₹904.80
2026-10-23: ₹889.80
2026-10-27: ₹930.30
2026-10-29: ₹946.50
2026-10-30: ₹944.80

Drawdown from peak

0% -26% -52% Feb '19Dec '22Oct '26 0% -26% -52% Feb '19Dec '22Oct '26
Largest drawdowns

-52.1% (2024-01 peak to 2025-03 low, recovered 2026-02)

-47.4% (2021-08 peak to 2022-02 low, recovered 2022-07)

-34.2% (2019-04 peak to 2019-06 low, recovered 2020-06)

Most recent volume spikes

2026-10-23: 7.5x the 50-day median, price -6.5% that day

2026-09-08: 5.3x the 50-day median, price +4.4% that day

2026-09-01: 11.3x the 50-day median, price +11.9% that day

Beta is the slope of daily returns against a market-cap-weighted index of the sector's other listed companies, built from today's constituents (so it excludes companies no longer listed).

Where does it rank among Health Technology peers?

Each cell is the company's percentile rank among its Health Technology peers (non-financial companies) that month.
Darker is better-ranked.
Rows marked ↓ are inverted (lower debt, shorter cash cycle and a lower P/E rank higher).

ROCE
Op. margin
Revenue growth
EPS growth
Debt/equity ↓
Cash cycle ↓
P/E ↓
12M momentum
Nov '21Jul '22Jan '23Jul '23Jan '24Jul '24Jan '25Jul '25Jan '26Oct '26
Lower rank Higher rank

Percentiles use today's listed companies in the sector and need at least 5 peers with a value; grey cells have too few.
ROE is computed from net profit and book value where the source does not report it.

The Health Technology sector page Watch it move against Health Technology in the Observatory

What else looks like this?

Companies with the most similar financial profile today, regardless of industry.

CompanySectorSimilarityClosest on
ORISSA MINERALS DEVELOPMENT CO (ORISSAMINE)Non-Energy Minerals71%market cap, operating margin
GENESYS INTERNATIONAL CORPORAT (GENESYS)Technology Services58%debt/equity, revenue
SURAKSHA DIAGNOSTIC (SURAKSHA)Health Services56%revenue, market cap
ARTEMIS MEDICARE SERVICES (ARTEMISMED)Health Services55%EPS growth, debt/equity
YATHARTH HOSPITAL TRAUMA (YATHARTH)Health Services55%ROCE, P/E
BETA DRUGS (BETA)Health Technology57%market cap, revenue
SENORES PHARMACEUTICALS (SENORES)Health Technology54%operating margin, P/E
ANLON HEALTHCARE (AHCL)Health Technology51%promoter holding, revenue

Similarity is statistical, based on reported metrics; it does not imply similar business quality or future returns.

What happened next to similar setups

+5.2%typical 12-month return vs the marketNot meaningfully different from the base rate
  • We found 50 past situations where a non-financial company looked like SAKAR HEALTHCARE LIMITED today on valuation, return on capital, margins, debt, growth, price momentum, size and volatility.
  • Over the following 12 months the middle half of them returned −40% to +37% vs the market, against −3% for all non-financial companies in the same months.
  • The gap against the base rate (+8.0%, 80% range −18.0% to +13.3%) is within what chance and overlapping periods produce.

Where the 50 outcomes landed

−100%−50%0%+50%+100%
HILTON · Jul 2023: −62.6% vs market
BIOFILCHEM · Oct 2020: −62.1% vs market
MOS · Mar 2025: −61.9% vs market
NEULANDLAB · Mar 2021: −60.1% vs market
GENESYS · Dec 2024: −54.9% vs market
AARTIDRUGS · Sep 2020: −51.9% vs market
ORCHPHARMA · Oct 2024: −51.4% vs market
PANSARI · Nov 2021: −50.8% vs market
HIKAL · Aug 2021: −49.3% vs market
TERASOFT · Oct 2025: −46.3% vs market
MATRIMONY · Feb 2021: −45.4% vs market
STERTOOLS · Apr 2023: −40.0% vs market
SOUTHWEST · May 2022: −39.8% vs market
RAMCOSYS · Nov 2020: −39.4% vs market
ARVSMART · Dec 2024: −35.5% vs market
INFOBEAN · Mar 2022: −34.8% vs market
TARIL · Feb 2025: −31.9% vs market
REPL · May 2021: −31.3% vs market
SHILPAMED · Aug 2020: −31.2% vs market
KRISHANA · Jan 2023: −23.6% vs market
MANINFRA · Feb 2022: −22.3% vs market
ASTEC · Jul 2020: −5.6% vs market
AGIIL · Oct 2025: −2.1% vs market
BECTORFOOD · Aug 2023: +1.7% vs market
KKCL · Apr 2023: +4.1% vs market
ICEMAKE · Apr 2023: +6.4% vs market
ANANTRAJ · Sep 2024: +7.4% vs market
TITAGARH · Sep 2023: +8.0% vs market
PARAS · Apr 2025: +9.5% vs market
AURIONPRO · Apr 2024: +12.2% vs market
JWL · Aug 2023: +13.8% vs market
LAURUSLABS · Nov 2020: +13.9% vs market
SERVOTECH · Feb 2024: +17.7% vs market
BORORENEW · Oct 2021: +21.0% vs market
HSCL · Jan 2024: +21.9% vs market
FOCUS · Feb 2023: +28.1% vs market
APOLLO · Jun 2023: +32.4% vs market
OLECTRA · Jun 2022: +37.8% vs market
JSLL · Jun 2025: +38.9% vs market
GANESHHOU · Jan 2023: +51.2% vs market
KERNEX · Apr 2022: +52.0% vs market
SHAILY · Apr 2025: +55.1% vs market
TEJASNET · Aug 2021: +56.6% vs market
CARTRADE · Jun 2025: +58.2% vs market
GREENPANEL · Aug 2021: +62.3% vs market
AMBER · Feb 2020: +73.2% vs market
ANUP · Nov 2023: +121.8% vs market
SANGHVIMOV · Apr 2023: +130.2% vs market
KAYNES · Dec 2023: +141.5% vs market
ACUTAAS · May 2025: +160.7% vs market
Similar setups +5.2%All companies −2.8%← worse than the marketbetter than the market →

Each dot is one past situation (hover or tap for details) · Solid dots are the closest matches, listed below · Shaded is the middle half of all companies in the same months · 4 beyond the range shown, drawn at the edge

Similar setups' median
+5.2%
All companies' median
−2.8%
Beat the market
54% vs 47%

50 past situations · 50 companies · 38 months · 2020–2025

The closest matches

CompanyWhenP/EROCE12M mom.DrawdownNext 12 months
SOUTHWEST
Energy Minerals		 May 2022 56x13% +448%−17% −40%
SHAILY
Process Industries		 Apr 2025 84x14% +141%−21% +55%
TERASOFT
Technology Services		 Oct 2025 57x11% +526%−5% −46%
MANINFRA
Finance		 Feb 2022 118x10% +330%−21% −22%
CARTRADE
Technology Services		 Jun 2025 60x8% +118%−6% +58%
Show the other 3 matches
CompanyWhenP/EROCE12M mom.DrawdownNext 12 months
ASTEC
Process Industries		 Jul 2020 44x20% +167%−15% −6%
APOLLO
Electronic Technology		 Jun 2023 61x11% +363%−5% +32%
REPL
Industrial Services		 May 2021 61x12% +814%−4% −31%
How reliable is this?

Matched on P/E, P/S, ROCE, operating margin, debt/equity, interest cover, revenue growth, 12-month momentum, drawdown from 12-month high, size and volatility. Closest on: P/E, debt/equity and interest cover. One match per company and at most 7 from any one month.

Independent periods: the matches fall in 6 distinct 12-month windows. Matches from nearby months share the same market conditions, so fewer windows means less evidence.

How this is built

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to SAKAR HEALTHCARE LIMITED. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

Methodology

How historical analogs are built

Data as of 2026-10-30. Outcome pool: Jan 2020 to Oct 2025.

For every company we look at the situation it is in today (valuation, return on capital, margins, debt, growth, 12-month price momentum, drawdown, size and volatility) and find past company-months that looked most like it. We then show what happened to those past situations over the following 12 months, measured against the ApnaFunda All index and against the base rate. It describes history. It does not predict anything.

What is compared

FeatureWeightNon-financialFinancial
P/E1yesyes
P/S1yes—
P/B1—yes
ROCE1yes—
operating margin1yes—
ROE1—yes
debt/equity0.75yes—
interest cover0.5yes—
revenue growth0.75yesyes
12-month momentum1yesyes
drawdown from 12-month high0.75yesyes
size0.75yesyes
volatility0.5yesyes

Weights were set by judgement before any outcome was looked at and are never tuned on results. Loss-making companies (negative P/E or net profit) are only matched with other loss-making companies. Banks, NBFCs and insurers are compared only with each other and use a different feature set. Every feature is converted, month by month, to its rank among companies in the same pool in that month, so a P/E of 30 in a hot market and a P/E of 22 in a cold one can match if both were equally expensive for their time. Only that month's data is used.

How closeness and the sample are defined

Distance is the weighted root-mean-square gap between the standardised features both companies have. A match needs at least 70% of the query's feature weight, a distance of at most 0.9, and 30 matches at minimum to be shown. We keep up to 50 matches with these exclusions: never the company itself, one match per company (its closest month), and at most 7 from any one calendar month so a single market episode cannot dominate.

Base rate

The base rate is the distribution of 12-month returns, relative to the market, of every eligible company-month in the same pool, with each month weighted to match the months the analogs came from. It answers: how did a random company do in these same months? Because matches from nearby months share the same market conditions, we also report the number of distinct 12-month windows behind a result, and a bootstrap that resamples months decides whether the analog median differs from the base rate at all. "Not meaningfully different" is the usual outcome and the page copy is written for it.

Limits you should know

  • One market period. The outcome pool covers 2020–2025 only (70 months), including the 2020 crash and the 2020–21 rally.
  • Survivorship. Only companies listed today are included. Delisted and bankrupt companies are missing, which flatters past outcomes, particularly for distressed-looking setups.
  • Price return only. Dividends are excluded, and the benchmark is an ApnaFunda market-cap-weighted index of the same listed companies, not an official index.
  • Reporting lag. Fundamentals are matched on an assumed 60-day lag after the quarter end, not on real announcement dates.
  • Pools: non-financial: 97,430 company-months from 2000 companies; financial: 5,632 company-months from 106 companies. 2240 companies currently have a result; the rest are suppressed because too few comparable situations exist.

Does it work? A walk-forward check

The walk-forward check has not been run for this build, so skill is shown as not yet measured.

Disclaimer

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to any company shown. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.
Monthly history (77 months)
MonthP/ERevenue (TTM)ROEROCEDebt / Equity
2026-1058.2x₹272 cr11.1%12.0%0.2x
2026-0967.4x₹272 cr11.1%12.0%0.2x
2026-0863.0x₹252 cr9.6%12.0%0.2x
2026-0764.6x₹252 cr9.6%12.0%0.2x
2026-0661.2x₹252 cr9.6%12.0%0.2x
2026-0570.1x₹231 cr9.1%9.0%0.3x
2026-0455.2x₹231 cr9.1%9.0%0.3x
2026-0343.8x₹231 cr9.1%9.0%0.3x
2026-0256.1x₹204 cr7.3%9.0%0.3x
2026-0144.3x₹204 cr7.3%9.0%0.3x
2025-1246.4x₹204 cr7.3%9.0%0.3x
2025-1141.8x₹189 cr7.3%9.0%0.3x
2025-1040.2x₹189 cr7.3%9.0%0.3x
2025-0939.9x₹189 cr7.3%9.0%0.3x
2025-0841.2x₹177 cr6.3%9.0%0.3x
2025-0743.0x₹177 cr6.3%9.0%0.3x
2025-0644.1x₹177 cr6.3%9.0%0.3x
2025-0546.4x₹170 cr5.7%7.0%0.3x
2025-0439.9x₹170 cr5.7%7.0%0.3x
2025-0331.1x₹170 cr5.7%7.0%0.3x
2025-0242.4x₹164 cr4.6%7.0%0.3x
2025-0147.8x₹164 cr4.6%7.0%0.3x
2024-1252.0x₹164 cr4.6%7.0%0.3x
2024-1158.4x₹155 cr4.2%7.0%0.3x
2024-1059.4x₹155 cr4.2%7.0%0.3x
2024-0960.5x₹155 cr4.2%7.0%0.3x
2024-0856.9x₹153 cr4.6%7.0%0.3x
2024-0760.6x₹153 cr4.6%7.0%0.3x
2024-0658.5x₹153 cr4.6%7.0%0.3x
2024-0549.5x₹133 cr7.5%9.0%0.7x
2024-0452.3x₹133 cr7.5%9.0%0.7x
2024-0355.0x₹133 cr7.5%9.0%0.7x
2024-0255.1x₹133 cr7.5%9.0%0.7x
2024-0163.7x₹133 cr7.5%9.0%0.7x
2023-1259.7x₹133 cr7.5%9.0%0.7x
2023-1158.4x₹133 cr7.5%9.0%0.7x
2023-1050.0x₹133 cr7.5%9.0%0.7x
2023-0950.8x₹133 cr7.5%9.0%0.7x
2023-0853.3x₹133 cr7.5%9.0%0.7x
2023-0738.5x₹133 cr7.5%9.0%0.7x
2023-0638.3x₹133 cr7.5%9.0%0.7x
2023-0527.4x₹128 cr11.8%12.0%0.7x
2023-0424.3x₹128 cr11.8%12.0%0.7x
2023-0322.5x₹128 cr11.8%12.0%0.7x
2023-0225.3x₹128 cr11.8%12.0%0.7x
2023-0125.6x₹128 cr11.8%12.0%0.7x
2022-1225.2x₹128 cr11.8%12.0%0.7x
2022-1130.4x₹128 cr11.8%12.0%0.7x
2022-1028.4x₹128 cr11.8%12.0%0.7x
2022-0923.3x₹128 cr11.8%12.0%0.7x
2022-0823.7x₹128 cr11.8%12.0%0.7x
2022-0722.3x₹128 cr11.8%12.0%0.7x
2022-0618.1x₹128 cr11.8%12.0%0.7x
2022-0523.5x₹95 cr11.1%13.0%0.4x
2022-0420.1x₹95 cr11.1%13.0%0.4x
2022-0319.8x₹95 cr11.1%13.0%0.4x
2022-0215.9x₹95 cr11.1%13.0%0.4x
2022-0121.5x₹95 cr11.1%13.0%0.4x
2021-1223.8x₹95 cr11.1%13.0%0.4x
2021-1120.5x₹95 cr11.1%13.0%0.4x
2021-1022.4x₹95 cr11.1%13.0%0.4x
2021-0923.1x₹95 cr11.1%13.0%0.4x
2021-0823.9x₹95 cr11.1%13.0%0.4x
2021-0726.3x₹95 cr11.1%13.0%0.4x
2021-0622.9x₹95 cr11.1%13.0%0.4x
2021-0522.8x₹83 cr12.3%—0.2x
2021-0418.1x₹83 cr12.3%—0.2x
2021-0317.6x₹83 cr12.3%—0.2x
2021-0214.5x₹83 cr12.3%—0.2x
2021-0116.2x₹83 cr12.3%—0.2x
2020-1215.3x₹83 cr12.3%—0.2x
2020-1112.6x₹83 cr12.3%—0.2x
2020-1013.9x₹83 cr12.3%—0.2x
2020-0912.3x₹83 cr12.3%—0.2x
2020-0811.7x₹83 cr12.3%—0.2x
2020-078.6x₹83 cr12.3%—0.2x
2020-0611.9x₹83 cr12.3%—0.2x

Methodology and data notes

Methodology

Methodology and data notes

All figures come from public exchange prices and screener.in financial statements. Quarterly and annual results are shown from 60 days after the period end, so a month never uses a result before it would plausibly have been published. Statements are the latest versions, which may include later restatements.

Sector medians, percentiles and indices use today's listed companies in the sector (survivorship bias). Prices are adjusted for splits and bonus issues; around a corporate action the fundamentals may lag the price by up to a month, and affected sections are hidden.

The return decomposition uses price = P/E × net profit ÷ share count. The reverse DCF uses a fixed 12% cost of equity, a 10-year horizon and a 15x terminal P/E, and is an illustration only. Events, flags and twins follow fixed rules and thresholds described next to each section.

Feedback